Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02194582 · ClinicalTrials.gov registry record
Genetic Causes of FSGS, Nephrotic Syndrome, or Kidney Failure
A clinical trial of End Stage Renal Disease and Focal Segmental Glomerulosclerosis, sponsored by Beth Israel Deaconess Medical Center.
- Active
- Registry status
- 2,050
- Enrollment target
- 1
- Study location
NCT02194582: Active study of End Stage Renal Disease and Focal Segmental Glomerulosclerosis, sponsored by Beth Israel Deaconess Medical Center.
NCT02194582 is a study of End Stage Renal Disease and Focal Segmental Glomerulosclerosis that is active but no longer recruiting, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 2,050 participants, above the 810-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (153% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02194582, a study of End Stage Renal Disease and Focal Segmental Glomerulosclerosis, is active but no longer recruiting, sponsored by Beth Israel Deaconess Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- 2,050 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators are trying to learn more about the cause of kidney diseases such as Focal Segmental Glomerulosclerosis (FSGS) and Nephrotic syndrome by studying genetics. The investigators are interested in discovering which genes play a role in causing a predisposition to FSGS/NS. The investigators also want to learn why FSGS/NS can run in families. Participation in our study involves a saliva sample and a urine sample that you can give from home. There is no cost to participate. All information is kept private and confidential. The investigators also like to include healthy volunteers (parents, spouses) if interested/available but of course this is completely optional.
Primary Outcome
This is an ongoing study for research purposes only.
Conditions Studied
Study Locations (1)
Massachusetts
- BIDMC - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,050 participants |
| Start Date | 1996-06 |
| Est. Completion | 2035-01 |
What the registry record for NCT02194582 still lists
NCT02194582 is an observational study that tracks outcomes without assigning an intervention. Its 2,050 participants enrollment target places it among the larger protocols in the corpus, above the 810-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (153% higher).
The record links to 5 conditions, with End Stage Renal Disease appearing as the primary indexed condition, and to 0 interventions.
NCT02194582 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02194582 about?
NCT02194582 is a clinical study titled "Genetic Causes of FSGS, Nephrotic Syndrome, or Kidney Failure". The investigators are trying to learn more about the cause of kidney diseases such as Focal Segmental Glomerulosclerosis (FSGS) and Nephrotic syndrome by studying genetics. The investigators are interested in discovering which genes play a role in causing a predisposition to FSGS/NS. The investigato...
What is the current status of trial NCT02194582?
This trial is currently active not recruiting. The enrollment target is 2,050 participants. The study started on 1996-06. Estimated completion is 2035-01.
What conditions does trial NCT02194582 study?
This clinical trial studies the following conditions: End Stage Renal Disease, Focal Segmental Glomerulosclerosis, Kidney Failure, Nephrotic Syndrome, Unexplained Proteinuria.
Who is sponsoring clinical trial NCT02194582?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02194582 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for End Stage Renal Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02194582's enrollment target sits among peer trials
2,050 5th of 86 higher than 82 of 86 other End Stage Renal Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other End Stage Renal Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study
RECRUITING · NA
-
Drug Interaction Potential of Pro-Inflammatory Conditions
RECRUITING
-
PReSeRVE-HD: Observational Study of the Merit HeRO® Graft and Super HeRO® in Patients on Hemodialysis
RECRUITING
-
Maturation of Arteriovenous Fistula With Automated Sonography Assessments Trial
RECRUITING · NA
-
AMSC for Reducing Anastomotic Stenosis in Primary Arteriovenous Anastomoses
RECRUITING · Phase 1
-
Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05050084 · 2,050 participants · Phase 3
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
- NCT05688982 · 2,049 participants · NA
MOLAR: Mapping Oral Health and Local Area Resources
- NCT06833476 · 2,044 participants
TTVR STRONG Under Coverage With Evidence Development (CED) Study
- NCT05138718 · 2,041 participants
FDG an Myocardial Infarction: The PIAF Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia